Amgen (NASDAQ:AMGN)‘s stock had its “buy” rating restated by investment analysts at TheStreet in a note issued to investors on Tuesday, Stock Ratings Network.com reports.
The analysts wrote, “Amgen (AMGN) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.”
Other equities research analysts have also recently issued reports about the stock. Analysts at Ned Davis Research upgraded shares of Amgen from a “neutral” rating to a “buy” rating in a research note to investors on Monday, July 8th. Separately, analysts at RBC Capital reiterated an “outperform” rating on shares of Amgen in a research note to investors on Wednesday, June 19th. They now have a $120.00 price target on the stock.
Thirteen equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Amgen currently has a consensus rating of “Buy” and an average target price of $111.00.
Amgen (NASDAQ: AMGN) traded down 1.64% on Tuesday, hitting $107.16. Amgen has a 1-year low of $76.18 and a 1-year high of $114.95. The stock’s 50-day moving average is currently $99.68. The company has a market cap of $80.367 billion and a price-to-earnings ratio of 18.44.
Amgen Inc is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.